These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 14976227)
1. Potent and metabolically stable agonists for protease-activated receptor-2: evaluation of activity in multiple assay systems in vitro and in vivo. Kawabata A; Kanke T; Yonezawa D; Ishiki T; Saka M; Kabeya M; Sekiguchi F; Kubo S; Kuroda R; Iwaki M; Katsura K; Plevin R J Pharmacol Exp Ther; 2004 Jun; 309(3):1098-107. PubMed ID: 14976227 [TBL] [Abstract][Full Text] [Related]
2. Binding of a highly potent protease-activated receptor-2 (PAR2) activating peptide, [3H]2-furoyl-LIGRL-NH2, to human PAR2. Kanke T; Ishiwata H; Kabeya M; Saka M; Doi T; Hattori Y; Kawabata A; Plevin R Br J Pharmacol; 2005 May; 145(2):255-63. PubMed ID: 15765104 [TBL] [Abstract][Full Text] [Related]
3. 2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist. McGuire JJ; Saifeddine M; Triggle CR; Sun K; Hollenberg MD J Pharmacol Exp Ther; 2004 Jun; 309(3):1124-31. PubMed ID: 14976230 [TBL] [Abstract][Full Text] [Related]
4. 2-Furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice. Kawabata A; Oono Y; Yonezawa D; Hiramatsu K; Inoi N; Sekiguchi F; Honjo M; Hirofuchi M; Kanke T; Ishiwata H Br J Pharmacol; 2005 Jan; 144(2):212-9. PubMed ID: 15655521 [TBL] [Abstract][Full Text] [Related]
5. Mechanisms underlying enhanced vasorelaxant response to protease-activated receptor 2-activating peptide in type 2 diabetic Goto-Kakizaki rat mesenteric artery. Matsumoto T; Ishida K; Taguchi K; Kobayashi T; Kamata K Peptides; 2009 Sep; 30(9):1729-34. PubMed ID: 19540892 [TBL] [Abstract][Full Text] [Related]